Here are four things to know:
1. The first-in-human study included 60 subjects and was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ABP-700.
2. Study results showed linear dose-proportional pharmacokinetics and pharmacodynamic effects, which were rapidly reversible.
3. Adverse events were mild with the exception of one subject with moderate tachycardia. No serious adverse events were reported.
4. The results were presented at the 2015 Annual Dutch Society of Anesthesiology Conference in Maastricht, Netherlands.
More articles on anesthesia:
Dr. Lawrence Lavine travels to Guatemala on medical mission trip — 4 quick facts
Dr. Murray Kalish receives Physician Advocacy award — 3 quick notes
Quantum creates anesthesia subsidiary, acquires DA Management — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.